This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Comparing Different Routes and Doses of Phytonadione (Vitamin K) for Reversing Warfarin Treated Patients With Hip Fracture Before Surgery

This study has been withdrawn prior to enrollment.
(Enrollment problems)
Information provided by:
HaEmek Medical Center, Israel Identifier:
First received: May 18, 2009
Last updated: June 21, 2015
Last verified: June 2015

It is well known that femoral neck fractures carry a significant increase in patients' mortality and that surgical intervention is the preferred treatment.

Any delay in operating on such patients would inevitably increase their risk of developing complications. One of the reasons for such unintentional delay would be the hypercoagulative status of patients taking warfarin. The CHEST 2008 guidelines suggest reversing warfarin with Vitamin K for patients who need urgent operation. The aim of this study is to compare different roots and doses of Vitamin K.

Condition Intervention
Bleeding Complications Drug: Phytonadione

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by HaEmek Medical Center, Israel:

Primary Outcome Measures:
  • International normalized ratio (INR) </= 1.2 [ Time Frame: 3 days ]

Secondary Outcome Measures:
  • Bleeding [ Time Frame: 6 weeks ]
  • Complications [ Time Frame: 6 weeks ]

Enrollment: 0
Study Start Date: May 2009
Study Completion Date: April 2010
Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: PO (by mouth)
2.5 mg P.O Vitamin K
Drug: Phytonadione
2.5 mg po
Other Name: vitamin k
Active Comparator: IV (intravenous )
0.5 mg IV Vitamin K
Drug: Phytonadione
0.5 mg IV
Other Name: vitamin k


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • hip fracture patients on warfarin

Exclusion Criteria:

  • pregnancy
  • vitamin k sensitivity
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00905229

Haemek Medical Center
Afula, Israel
Sponsors and Collaborators
HaEmek Medical Center, Israel
  More Information

Responsible Party: orit semana, haemek medical center Identifier: NCT00905229     History of Changes
Other Study ID Numbers: 02-09
Study First Received: May 18, 2009
Last Updated: June 21, 2015

Keywords provided by HaEmek Medical Center, Israel:
hip fracture
vitamin k
INR level

Additional relevant MeSH terms:
Hip Fractures
Femoral Fractures
Fractures, Bone
Wounds and Injuries
Hip Injuries
Leg Injuries
Vitamin K
Vitamin K 1
Growth Substances
Physiological Effects of Drugs
Antifibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Coagulants processed this record on September 25, 2017